Indian Journal of Psychological Medicine
  Home | About Us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Contact | Advertise | Submission | Login 
Users Online: 459 
Wide layoutNarrow layoutFull screen layoutHome Print this page Email this page Small font sizeDefault font sizeIncrease font size


 
 Table of Contents    
LETTERS TO EDITOR
Year : 2020  |  Volume : 42  |  Issue : 2  |  Page : 200-202  

Relationship between matrix metalloproteinase-9 and lifetime history of suicidal behavior in remitted patients with bipolar I disorder: A Cross-Sectional Pilot Study


1 Department of Psychiatry, Sree Lakshmi Narayana Institute of Medical Sciences, Puducherry, India
2 Department of Psychiatry, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed-to-be University), Puducherry, India
3 Department of Psychiatry, JIPMER, Puducherry, India
4 Department of Biochemistry, JIPMER, Puducherry, India
5 Department of Psychiatry and NDDTC, All India Institute of Medical Sciences, New Delhi, India
6 Panimalar Medical College Hospital and Research Institute, Chennai, Tamil Nadu, India

Date of Submission30-Jul-2019
Date of Decision28-Aug-2019
Date of Acceptance27-Jan-2020
Date of Web Publication9-Mar-2020

Correspondence Address:
Dr. Karthick Subramanian
Department of Psychiatry, Mahatma Gandhi Medical College and Research Institute (MGMCRI), Sri Balaji Vidyapeeth (Deemed-to-be University), Pondicherry - 607 402
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJPSYM.IJPSYM_320_19

Rights and Permissions

How to cite this article:
Chandrasekaran V, Subramanian K, Kattimani S, Nandheesha H, Sarkar S, Penchilaiya V. Relationship between matrix metalloproteinase-9 and lifetime history of suicidal behavior in remitted patients with bipolar I disorder: A Cross-Sectional Pilot Study. Indian J Psychol Med 2020;42:200-2

How to cite this URL:
Chandrasekaran V, Subramanian K, Kattimani S, Nandheesha H, Sarkar S, Penchilaiya V. Relationship between matrix metalloproteinase-9 and lifetime history of suicidal behavior in remitted patients with bipolar I disorder: A Cross-Sectional Pilot Study. Indian J Psychol Med [serial online] 2020 [cited 2020 Mar 28];42:200-2. Available from: http://www.ijpm.info/text.asp?2020/42/2/200/280281



To the editor,

Bipolar disorder (BD) is a chronic recurring mood disorder with a lifetime prevalence of 1.06%.[1] BD is associated with comorbid substance use, medical illnesses, suicidal behaviors, and biorhythm irregularities, leading to increased morbidity and mortality.[2],[3]

Suicidality is one of the preventable causes of mortality in BD. The prevalence rates of suicide attempts (25–50%) and suicidal deaths (8–19%) are higher among BD-I patients than the general population.[4] There are various biopsychosocial risk factors for suicidality in BD.[5]

Neurotrophins such as brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) are actively researched as biomarkers in BD. BDNF is biologically activated by MMP-9, leading to effective neuronal growth and synaptic plasticity.[6] Studies reveal that suicidality and BD are independently associated with raised MMP-9 levels.[7],[8]

The present study aimed to evaluate the relationship between MMP-9 levels and lifetime history of suicide attempt in remitted BD-I patients.


   Materials and Methods Top


The study was cross-sectional in design, and the participants were recruited by purposive sampling in a tertiary-cum-teaching hospital in southern India. Patients with BD-I (n = 150) were enrolled into the parent study, which analyzed the course and outcome of BD-I among Indian patients.[9] A subset of patients (n = 60) from the parent study was studied for neurotrophic markers (MMP-9) and cognitive functions in another unpublished research. Those patients with data on illness course, suicidality, and neurotrophic markers were included in the present pilot study.

Patients aged 18–65 years, with BD-I diagnosis as per Structured Clinical Interview for DSM-IV-TR Axis-I Disorders (SCID-I),[10] with illness duration of minimum 3 years, and currently in clinical remission as defined by Hamilton Depression Rating Scale (HDRS) score <8 and Young Mania Rating Scale (YMRS) score <7 were included.[11],[12] Patients with active substance use in the past 12 weeks or having medical/neurological illnesses were excluded.

Sociodemographic data were collected using a semi-structured proforma. The illness course was systematically charted in the National Institute of Mental Health – Life Chart Methodology (Retrospective) chart.[13] The severity of lifetime suicide behavior was assessed using the Columbia Suicide Severity Rating Scale (C-SSRS).[14] Serum MMP-9 levels were assessed using the enzyme-linked immunoassay method. Informed consent was obtained from all the participants, and the Institute Ethics Committee approved the study protocol.[9]

Non-parametric tests were chosen for this sample due to the non-uniform distribution of MMP-9 values. After appropriate descriptive analyses, Mann–Whitney U test was used for comparison for dichotomous variables and Kendall's τ b was used for non-parametric correlation with the continuous data. No sensitivity analysis was performed. Statistical analyses were conducted using SPSS 19 (IBM Corp, Armonk, NY), and P < 0.05 was considered significant.


   Results Top


Remitted BD-I patients (n = 25) were recruited. The mean age was 34.0 years (range 22–56 years), with 60% being females. The participants were mainly home-makers, and were educated above 10th grade. A major proportion (92%) belonged to the lower socioeconomic status. The mean duration of BD was 12.1 years (range 3–24 years), with a mean of 5 episodes (range 2–13). Eleven participants (44%) had unipolar mania. The lifetime history of a suicide attempt was noted in 20% (n = 5) of the participants.

In the present study, only 6 out of 25 subjects (24%) had MMP-9 levels within the standard normal range (11.4-59.4 ng/ml), with the remainder having less than normal levels. The mean MMP-9 level in the entire sample was 9.09 ± 11.58 ng/ml. The levels of MMP-9 were higher in patients with a lifetime history of a suicide attempt when compared to those without (20.25 ± 169.49 ng/ml vs. 6.29 ± 8.24 ng/ml, Mann–Whitney U = 14.000, P = 0.014). MMP-9 levels negatively correlated with the age of the participants (Kendall's τ b = -0.264, P = 0.068) and the duration of BD (Kendall's τ b = -0.279, P = 0.057), with a trend toward significance [Table 1].
Table 1: Relationship of MMP-9 with clinical variables

Click here to view



   Discussion Top


The prevalence rate of suicide attempts in the study population was comparable to those observed in a previously reported study[15] A preponderance of T-allele versus C-allele of 1562C/T of the MMP-9 gene was found in BD patients compared to control subjects, leading to pro-inflammatory changes.[16],[17] Considering the neuroinflammatory hypothesis of BD, increased MMP-9 levels could be considered a marker of an inflammatory state.

In the current study, elevated MMP-9 levels were associated with a lifetime history of suicide attempt in BD, suggesting the role of a state marker for suicidality.[9] However, the evidence remains inconclusive on the nature of the association of MMP-9 with the illness phase (acute/remission). While some studies reported elevated MMP-9 during the remission phase,[17] some other studies have revealed increased MMP-9 during both acute and remission phases of depression.[18],[19] Variation of MMP-9 levels with age, as noted in previous studies, could not be replicated in the present study, probably due to the low sample size.[18]

Despite being one of the first Indian studies exploring the role of MMP-9 in suicidality, the study has the following limitations:

  • The present study is a pilot study with a small sample size, and a minuscule proportion with the variable of interest (i.e., suicidal attempts in the past) would have influenced the negative association between MMP-9 and clinical characteristics
  • Lack of a control group precludes an interpretation of MMP-9 levels as a marker of suicidality in BD-I
  • The retrospective study design had inherent recall bias.


Nevertheless, the present study emphasizes the need to assess newer markers such as MMP-9 in suicidality observed in BD. Future studies with a large sample size and a control group will help elucidate the role of biomarkers in suicidality associated with BD.

Financial support and sponsorship

Intramural research grant was utilized to purchase biomedical kits (No. JIP/Res/Intra-MD-MS/ first/04/2014).

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68:241-51.  Back to cited text no. 1
    
2.
Latalova K, Kamaradova D, Prasko J. Suicide in bipolar disorder: A review. Psychiatr Danub 2014;26:108-14.  Back to cited text no. 2
    
3.
Gonzalez R. The relationship between bipolar disorder and biological rhythms. J Clin Psychiatry 2014;75:e323-31.  Back to cited text no. 3
    
4.
Marangell LB, Bauer MS, Dennehy EB, Wisniewski SR, Allen MH, Miklowitz DJ, et al. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord 2006;8:566-75.  Back to cited text no. 4
    
5.
Galfalvy H, Oquendo MA, Carballo JJ, Sher L, Grunebaum MF, Burke A, et al. Clinical predictors of suicidal acts after major depression in bipolar disorder: A prospective study. Bipolar Disord 2006;8:586-95.  Back to cited text no. 5
    
6.
Kuzniewska B, Rejmak E, Malik AR, Jaworski J, Kaczmarek L, Kalita K. Brain-derived neurotrophic factor induces matrix metalloproteinase 9 expression in neurons via the serum response factor/c-Fos pathway. Mol Cell Biol 2013;33:2149-62.  Back to cited text no. 6
    
7.
Rosenblat JD, McIntyre RS. Bipolar disorder and inflammation. Psychiatr Clin North Am 2016;39:125-37.  Back to cited text no. 7
    
8.
Ventorp F, Barzilay R, Erhardt S, Samuelsson M, Träskman-Bendz L, Janelidze S, et al. The CD44 ligand hyaluronic acid is elevated in the cerebrospinal fluid of suicide attempters and is associated with increased blood-brain barrier permeability. J Affect Disord 2016;193:349-54.  Back to cited text no. 8
    
9.
Karthick S, Kattimani S, Rajkumar RP, Bharadwaj B, Sarkar S. Long term course of bipolar I disorder in India: Using retrospective life chart method. J Affect Disord 2015;173:255-60.  Back to cited text no. 9
    
10.
First MB, Spitzer RL, Gibbon M, Williams JBW. Struct Clin Interview DSM-IV-TR Axis Disord Res Version Patient Ed-IP. New York: Biometrics Research, New York State Psychiatric Institute; 2002.  Back to cited text no. 10
    
11.
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry J Ment Sci 1978;133:429-35.  Back to cited text no. 11
    
12.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.  Back to cited text no. 12
    
13.
Roy-Byrne P, Post RM, Uhde TW, Porcu T, Davis D, The longitudinal course of recurrent affective illness: Life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl 1985;317:1-34.  Back to cited text no. 13
    
14.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia–suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77.  Back to cited text no. 14
    
15.
Kattimani S, Subramanian K, Sarkar S, Rajkumar RP, Balasubramanian S. History of Lifetime suicide attempt in bipolar I disorder: Its correlates and effect on illness course. Int J Psychiatry Clin Pract 2017;21:118-24.  Back to cited text no. 15
    
16.
Rempe RG, Hartz AM, Bauer B. Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers. J Cereb Blood Flow Metab 2016;36:1481-507.  Back to cited text no. 16
    
17.
Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One [Internet] 2010;5:e9166.  Back to cited text no. 17
    
18.
Rybakowski JK, Remlinger-Molenda A, Czech-Kucharska A, Wojcicka M, Michalak M, Losy J. Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression. J Affect Disord 2013;146:286-9.  Back to cited text no. 18
    
19.
Bobińska K, Szemraj J, Czarny P, Galecki P. Role of MMP-2,MMP-7, MMP-9 and TIMP-2 in the development of recurren depressive disorder. J Affect Disord 2016;205:119-29.  Back to cited text no. 19
    



 
 
    Tables

  [Table 1]



 

Top
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Materials and Me...
   Results
   Discussion
    References
    Article Tables

 Article Access Statistics
    Viewed78    
    Printed0    
    Emailed0    
    PDF Downloaded11    
    Comments [Add]    

Recommend this journal